Andrea Botticelli

Pubblicazioni

Titolo Pubblicato in Anno
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index EUROPEAN JOURNAL OF CANCER 2021
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives CANCERS 2021
The role of opioids in cancer response to immunotherapy JOURNAL OF TRANSLATIONAL MEDICINE 2021
Standard of care and promising new agents for the treatment of mesenchymal triple-negative breast cancer CANCERS 2021
New immunological potential markers for triple negative breast cancer: IL18R1, CD53, TRIM, Jaw1, LTB, PTPRCAP DISCOVER ONCOLOGY 2021
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era JOURNAL OF TRANSLATIONAL MEDICINE 2021
Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view CLINICAL & TRANSLATIONAL ONCOLOGY 2021
The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study JOURNAL OF PERSONALIZED MEDICINE 2021
Anti–PD-1 and Anti–PD-L1 in head and neck cancer: a network meta-analysis FRONTIERS IN IMMUNOLOGY 2021
Metastatic renal cell carcinoma management: from molecular mechanism to clinical practice FRONTIERS IN ONCOLOGY 2021
Prediction of recurrence by Machine learning in salivary gland cancer patients after adjuvant (chemo)radiotherapy IN VIVO 2021
Role of chemotherapy in vulvar cancers: time to rethink standard of care? CANCERS 2021
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma EUROPEAN JOURNAL OF CANCER 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort JOURNAL OF TRANSLATIONAL MEDICINE 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial SCIENTIFIC REPORTS 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study JAMA ONCOLOGY 2021
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study JAMA ONCOLOGY 2021
The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon? FRONTIERS IN IMMUNOLOGY 2021
How to best exploit immunotherapeutics in advanced gastric cancer: Between biomarkers and novel cell-based approaches JOURNAL OF CLINICAL MEDICINE 2021

Progetti di Ricerca

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma